Literature DB >> 11354296

Apheresis as therapy for patients with severe sepsis and multiorgan dysfunction syndrome.

B G Stegmayr1.   

Abstract

Progressive multiorgan dysfunction syndrome may occur in the course of sepsis and septic shock as well as after various intoxications, pancreatitis, crush injuries, and major surgery. Despite conventional intensive care therapies, the prognosis in these patients is still poor. Apheresis, which uses more selective adsorption techniques, can lower the extent of toxins and cytokines in blood. This is achieved in clinical practice by, e.g., using polymyxin B as adsorbent. Although significantly lowered, the mortality is still about 50% with this technique. By unselective plasma exchange, the mortality is reduced down to 20 to 40%. A controlled and randomized study has shown a significant benefit. The centrifugation technique may be favorable over plasma filtration. Not only removal but also replacement with plasma seems important. In the future, probably selective techniques will be used in the early stages of sepsis while unselective plasma exchange may be useful in a disseminated situation.

Entities:  

Mesh:

Substances:

Year:  2001        PMID: 11354296     DOI: 10.1046/j.1526-0968.2001.005002123.x

Source DB:  PubMed          Journal:  Ther Apher        ISSN: 1091-6660


  4 in total

1.  Hyperferritinemia in the critically ill child with secondary hemophagocytic lymphohistiocytosis/sepsis/multiple organ dysfunction syndrome/macrophage activation syndrome: what is the treatment?

Authors:  Demet Demirkol; Dincer Yildizdas; Benan Bayrakci; Bulent Karapinar; Tanil Kendirli; Tolga F Koroglu; Oguz Dursun; Nilgün Erkek; Hakan Gedik; Agop Citak; Selman Kesici; Metin Karabocuoglu; Joseph A Carcillo
Journal:  Crit Care       Date:  2012-12-12       Impact factor: 9.097

Review 2.  Therapeutic Plasma Exchange: A potential Management Strategy for Critically Ill COVID-19 Patients.

Authors:  Seena Tabibi; Tara Tabibi; Rosalynn R Z Conic; Nassim Banisaeed; Michael B Streiff
Journal:  J Intensive Care Med       Date:  2020-07-15       Impact factor: 3.510

Review 3.  Severe COVID-19, Another Piece in the Puzzle of the Hyperferritinemic Syndrome. An Immunomodulatory Perspective to Alleviate the Storm.

Authors:  Piero Ruscitti; Onorina Berardicurti; Paola Di Benedetto; Paola Cipriani; Annamaria Iagnocco; Yehuda Shoenfeld; Roberto Giacomelli
Journal:  Front Immunol       Date:  2020-05-28       Impact factor: 7.561

Review 4.  The hyperferritinemic syndrome: macrophage activation syndrome, Still's disease, septic shock and catastrophic antiphospholipid syndrome.

Authors:  Cristina Rosário; Gisele Zandman-Goddard; Esther G Meyron-Holtz; David P D'Cruz; Yehuda Shoenfeld
Journal:  BMC Med       Date:  2013-08-22       Impact factor: 8.775

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.